PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
2 ビュー
• 07/14/23
0
0
埋め込む
administrator
加入者
Visit http://www.ecancer.org for more
Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント